← Patent-cliff monitor small molecule YUTREPIA TREPROSTINIL SODIUM
Loss of exclusivity May 2037 latest FDA-listed patent expiry
Drug detail Brand name YUTREPIA Active ingredient TREPROSTINIL SODIUM Strength EQ 0.0795MG BASE/INH Dosage form POWDER Route INHALATION Modality Small molecule FDA approval May 2025 Marketing status RX
Listed patents Patent Expires Type 11712442 May 2037 use U-4200 10898494 May 2037 use U-4200 11660304 May 2037 use U-4200 11744836 May 2037 product 11744835 May 2037 product 12390475 May 2037 product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.